Kodiak Sciences (NASDAQ:KOD - Get Free Report) was upgraded by JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating in a research note issued to investors on Thursday, Marketbeat reports. The firm presently has a $15.00 price objective on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 74.01% from the stock's previous close.
Kodiak Sciences Stock Up 1.2%
Shares of KOD opened at $8.62 on Thursday. The stock has a market capitalization of $454.79 million, a P/E ratio of -2.37 and a beta of 2.41. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $11.60. The company has a 50 day moving average of $5.33 and a 200-day moving average of $4.40.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02). On average, sell-side analysts anticipate that Kodiak Sciences will post -3.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kodiak Sciences
Several hedge funds have recently added to or reduced their stakes in KOD. Price T Rowe Associates Inc. MD lifted its holdings in Kodiak Sciences by 10,982.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company's stock valued at $12,622,000 after purchasing an additional 1,257,063 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Kodiak Sciences during the 4th quarter valued at $11,338,000. Boxer Capital Management LLC acquired a new stake in Kodiak Sciences during the 4th quarter valued at $9,950,000. Point72 Asset Management L.P. acquired a new stake in Kodiak Sciences during the 4th quarter valued at $5,211,000. Finally, Silverarc Capital Management LLC lifted its holdings in Kodiak Sciences by 100.0% during the 4th quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company's stock valued at $9,950,000 after purchasing an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access